SGLT2 inhibitors in patients with hypertrophic cardiomyopathy and type 2 diabetes: Mortality benefit despite increased cardiovascular risk profile

Authors

Karldon Iwuchukwu Nwaezeapu
Godbless Ajenaghughrure
Ekow Essien, Advocate Health - MidwestFollow
Abena Agyekum

Recommended Citation

Nwaezeapu KI, Ajenaghughrure G, Essien E, Agyekum A. SGLT2 Inhibitors in Patients with Hypertrophic Cardiomyopathy and Type 2 Diabetes: Mortality Benefit Despite Increased Cardiovascular Risk Profile. American Heart Journal. 2025;290:8-9. doi:10.1016/j.ahj.2025.07.029

Type

Abstract